In patients with chronic kidney disease, does supplementation with N‑acetylcysteine, taurine, and an alpha‑keto‑analogue help maintain stable serum creatinine levels?

NAC, Taurine, and Alpha-Ketoanalogues Do Not Have Guideline Support for Maintaining Creatinine in CKD

The most recent KDIGO 2024 guidelines do not recommend N-acetylcysteine (NAC), taurine, or alpha-ketoanalogues for maintaining stable serum creatinine levels in CKD patients. Instead, the evidence-based standard of care focuses on RAS inhibitors, SGLT2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists 1, 2.

What the Guidelines Actually Recommend

The KDIGO 2024 guidelines provide clear, evidence-based recommendations for slowing CKD progression that prioritize morbidity, mortality, and quality of life outcomes—not simply maintaining creatinine levels:

First-Line Therapies with Strong Evidence

• RAS Inhibitors (ACEi/ARB): Recommended for CKD patients with moderately-to-severely increased albuminuria (1B recommendation) 2
• SGLT2 Inhibitors: Strongly recommended (1A) for adults with CKD and eGFR ≥20 mL/min/1.73 m² with significant albuminuria or heart failure 2
• Nonsteroidal MRA (finerenone): Suggested (2A) for type 2 diabetes patients with persistent albuminuria despite maximal RASi therapy 2, 1

Protein Restriction with Ketoanalogues

The only dietary supplement with guideline support is ketoanalogue supplementation combined with very low-protein diets (0.28-0.43 g/kg/day) in CKD stages 3-5 patients who are metabolically stable and under close clinical supervision 3. This approach aims to reduce risk of ESKD/death (1A recommendation), not simply maintain creatinine levels.

The Evidence on NAC and Taurine

NAC: Conflicting and Concerning Data

The research evidence reveals significant problems with NAC for CKD management:

Analytical Interference: NAC can artificially lower serum creatinine measurements without improving actual kidney function 4. This effect is particularly pronounced with:

• Non-Jaffe creatinine assays (decrease of 3.24 μmol/L)
• Intravenous NAC administration (decrease of 31.10 μmol/L)
• No corresponding change in cystatin C levels, confirming this is assay interference, not true kidney function improvement 4

Mixed Clinical Results:

• One three-year cohort study showed NAC users had lower hemodialysis rates (4.8% vs 12.7%) 5
• However, multiple randomized controlled trials found no effect of NAC on serum creatinine or cystatin C in CKD patients 6, 7
• A combination study (NAC + pyridoxamine) showed modest eGFR improvement only in early CKD (eGFR >45) without metabolic acidosis 8

Taurine: Insufficient Evidence

Taurine is mentioned only in the context of pediatric parenteral nutrition formulations 9. There is no guideline or high-quality evidence supporting oral taurine supplementation for maintaining kidney function in CKD patients.

Alpha-Ketoanalogues: Context-Dependent

A 2024 meta-analysis of ketoanalogues combined with protein restriction showed 10:

• Higher GFR maintenance
• Decreased urea nitrogen and phosphorus
• Marginally lower ESKD risk in non-diabetic patients
• No benefit demonstrated for ketoanalogues alone without strict protein restriction

Critical Clinical Pitfalls

The Creatinine Trap

Do not rely on serum creatinine alone when using NAC. If NAC is being used for any reason in a CKD patient, the artificial lowering of creatinine could mask actual kidney function decline or delay diagnosis of acute kidney injury 4. Use cystatin C or measured GFR instead.

Monitoring Expectations with RAS Inhibitors

The guidelines explicitly state that a 10-30% rise in serum creatinine is expected and acceptable when initiating RAS inhibitors 2, 11, 2. This reflects the desired hemodynamic effect (reducing glomerular hyperfiltration) and is actually protective long-term. Only discontinue if creatinine rises >30% within 4 weeks 2.

Evidence-Based Algorithm for CKD Management

For all CKD patients, prioritize in this order:

1. Blood pressure control: Target SBP <120 mmHg when tolerated 1, 2

2. RAS inhibition: Start ACEi or ARB for patients with albuminuria (A2-A3) 2

   • Use maximum tolerated dose
   • Monitor creatinine/potassium at 2-4 weeks
   • Accept up to 30% creatinine rise

3. SGLT2 inhibitor: Add for patients with eGFR ≥20 and either ACR ≥200 mg/g or heart failure 2

   • Continue even if eGFR drops below 20 after initiation
   • The initial eGFR dip is expected and not harmful

4. Nonsteroidal MRA: Consider adding finerenone for diabetic patients with persistent albuminuria despite above therapies 2, 1

5. Protein restriction with ketoanalogues: Only for motivated patients under close supervision, targeting 0.55-0.60 g/kg/day total protein intake 3, 10

NAC, taurine, and standalone ketoanalogues are not part of this evidence-based algorithm.

Bottom Line

Focus on proven therapies that reduce mortality and ESKD progression—not supplements that may artificially alter creatinine measurements. The combination of RAS inhibitors, SGLT2 inhibitors, and appropriate blood pressure control represents the current standard of care with the strongest evidence for improving patient outcomes 1, 2.